Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics